Todd Asset Management LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Todd Asset Management LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 69.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 7,724 shares of the biopharmaceutical company’s stock after selling 17,268 shares during the quarter. Todd Asset Management LLC’s holdings in Pfizer were worth $222,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. AJOVista LLC purchased a new stake in Pfizer during the 4th quarter worth about $181,000. Provence Wealth Management Group lifted its holdings in shares of Pfizer by 4.6% in the fourth quarter. Provence Wealth Management Group now owns 9,056 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 397 shares in the last quarter. Sapient Capital LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $1,630,000. W Advisors LLC grew its stake in Pfizer by 14.5% during the fourth quarter. W Advisors LLC now owns 11,965 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 1,513 shares in the last quarter. Finally, Axxcess Wealth Management LLC increased its holdings in Pfizer by 20.0% during the 4th quarter. Axxcess Wealth Management LLC now owns 217,736 shares of the biopharmaceutical company’s stock worth $6,269,000 after acquiring an additional 36,311 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on PFE. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $36.00.

Pfizer Price Performance

PFE traded up $0.11 on Friday, hitting $27.81. 60,568,852 shares of the company were exchanged, compared to its average volume of 41,900,304. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The firm has a fifty day simple moving average of $26.88 and a two-hundred day simple moving average of $28.21.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.